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doi:10.1016/j.jfma.2011.07.009Background/Purpose: The aim of this study was to gain a better understanding of the current
incidence of Crohn’s disease (CD) in Taiwan and examine its clinical/genetic characteristics
because there has been a trend toward increased diagnosis in the Asia-Pacific area. The genetic
background seen in CD cases in Taiwan seems to be different from that in Western countries.
Methods: By reviewing the database in the National Taiwan University Hospital, CD patients
were identified by clinical, endoscopic, and imaging findings. The clinical characteristics were
recorded and analyzed. DNAwas extracted from the peripheral blood of patients after obtaining
informed consent. Polymerase chain reaction was performed with specific primers followed by
direct sequencing to determine the single-nucleotide polymorphisms ATG16L1, CCR6, IL12B,
IL23R, LRRK2, TNFSF2, and TNFSF15 CD-associated genes.
Results: Clinical data from110CDpatientswere examined from1988 to 2008,with amean follow-
up period of 4.5 years. There was a marked increase in new CD diagnosis, especially after 2004.
Among the 110 patients, 71men and 39 women, the age at diagnosis was 30.5 17.8 years (mean
 standard deviation). Stenosis occurred in 33.6% (37 of 110) and 40.9% (45 of 110) of patientswho
underwent surgery. The mortality rate was 2.7%, all because of sepsis. Genetic analysis of 39
patients showed that ATG16L1 and TNFSF15 were associated with susceptibility to CD in Taiwan.
Conclusion: Recently, the incidence of CD diagnosis in Taiwan has markedly increased. ATG16L1
and TNFSF15 are associated with CD in Taiwan.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.tw (J.-M. Wong).
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The inflammatory bowel diseases (IBDs), Crohn’s disease
(CD), and ulcerative colitis are common causes of chronic
gastrointestinal disease in the developed world. The
diseases are particularly common in young people and have
a major effect on the quality of life.1 The pathogenesis of
IBD is complex, and genetic and environmental factors both
contribute to its etiology.1,2 The first susceptibility gene
for CD was identified in 2001 and was initially named NOD2;
it was later renamed CARD15. Mutations in CARD15 are
strongly associated with CD in populations of European
descent. However, the NOD2/CARD15 mutations are absent
in Asian (Japan, Korea, China, Singapore, and Taiwan) CD
populations and controls.3e6
Although IBD was previously looked upon as an
uncommon disease in Taiwan (around 1500 patients in
Taiwan), according to our previous results, there has
recently been an increasing incidence of pediatric CD.7 We
have also demonstrated that the clinical characteristics of
our pediatric CD patients are similar to those of patients
from Western countries. However, the genetic background
of Taiwanese CD patients appears to differ from that of the
patients of Western descent because there was no NOD2,
toll-like receptor 4 mutation/polymorphism detected.4
Prediction of disease phenotype and response to themain
therapies has beena goal for physicians treating IBDpatients.
Some genotypic characteristics are associated with pheno-
typic presentation and influence the clinical course of IBD
and the likelihood of responding to certain therapies.8e20 We
expect that the optimal prediction of disease behavior and
response to therapymight result fromacomplexcombination
of clinical, biochemical, serological, and genetic factors.
To achieve the optimal predictors, we designed this
study to establish the genetic and phenotypic characteris-
tics of CD patients in Taiwan. Genetic analysis focused on
the previously reported polymorphisms that are associated
with clinical phenotypes (IL23R and TNFSF2)8e20 and those
recently identified IBD genes with functional meaning
(ATG16L1, CCR6, IL12B, LRRK2, and TNFSF15).2,21
Patients and methods
Patients
From 1988 to September 2008, we recruited 110 patients
who were treated for CD at the National Taiwan University
Hospital, a tertiary medical referral center in Taiwan. After
signing the informed consent document for participation in
our study, which was approved (9361701157) by the Insti-
tutional Review Board of the Ethics Committee of the
National Taiwan University Hospital, DNA was extracted
from whole venous blood. To analyze the clinical charac-
teristics of CD patients in Taiwan, the anatomical distri-
bution of the disease at the time of diagnosis and during
clinical follow-up was determined by endoscopic and/or
radiological evaluation with or without surgical interven-
tions. We collected clinical data, including age at diagnosis,
symptoms/signs, and the disease course of CD. The history
of laparotomy and/or appendectomy, the presence of
fistula, extraegastrointestinal tract manifestations, andthe clinical course of the patients were recorded and
analyzed. Follow-up of our patients started from the time
of diagnosis and ended in September 2008.
Criteria for CD diagnosis
Diagnosis of CD required the presence of at least two of the
following four criteria: (1) history of diarrhea and/or
abdominal pain for>3 months; (2) endoscopic identification
of segmental lesions of cobblestone appearance and/or
radiological evidence of stenosis in the small and/or large
bowel; (3) histological findings of transmural lymphocytic
infiltration and/or occurrence of epithelial granulomas with
giant cells of the Langerhans type; and (4) presence of
fistulas and/or abscesses in relation to the intestinal lesion.
DNA purification from whole blood and genotyping
Genomic DNA was purified from whole blood using the Vio-
gene blood genomic DNA extraction kit (Viogene, Taipei,
Taiwan) according to the standard protocol. Polymerase
chain reactions (PCRs) were performed with specific primers
(Table 1) using a GeneAmp PCR System 9600 or 9700 thermal
cycler (Applied Biosystems, Foster City, CA, USA). The PCR
products were purified using a QIAquick PCR Purification Kit
(QIAGEN, Hilden, Germany) according to themanufacturer’s
instructions. Finally, the PCR products were purified by
ethanol precipitation and analyzed by Genetic Analyzer ABI
PRISM 3100 or by the DNA Sequencer ABI PRISM 377 auto-
mated DNA sequencer (Applied Biosystems), according to
the manufacturer’s instructions. The sequencing primers
were the same as those used for the PCR amplifications.
Statistical analysis
Fisher’s exact test for categorical variables and Student
t test for continuous variables were used. A p value <0.05
was considered statistically significant. Logistic regression
analyses were used to analyze the association between
genotypes and allele types of various single-nucleotide
polymorphisms (SNPs), and risk of CD, odds ratios (ORs),
and 95% confidence intervals (CIs) were derived. The linear
trend of CD risk for the dose of risk allele among genotypes
was tested using the Cochran-Armitage trend test. The
haplotype analysis for five SNPs on TNFSF2 was performed
using HaploView software version 4.1.2
Results
Clinical manifestations
From 1988 to September 2008, a total of 110 CD patients
were enrolled for clinical analysis and 39 for genetic anal-
ysis. The median age at diagnosis was 30.5 years (range,
1.2e75 years). There were 71 male and 39 female patients,
with a male to female ratio of 1.8:1. The follow-up period
ranged from 0.5 months to 30 years, with a mean follow-up
of 4.5 years. The median interval from onset of disease to
diagnosis was 9.0 months (range, 3e36 months). Four (two
twins) of the 110 patients had a family history of CD (3.6%).
Table 1 Primers used for SNP polymerase chain reaction
and sequencing
SNPs Sequence
IL23R rs11209026
Forward TTGAGCAGAGTAAAGAGAATAGTAAT
Reverse TAAAGGAAAGACATTTGTAGAGAGTT
IL23R rs11465804
Forward GACACATGGAATTCTGGGCTA
Reverse TGTCCAGAAACTTAACACCTGATG
ATG16L1 rs2241880
Forward CACAGCTGACAGAGCCAAAA
Reverse TGTGCTGGCTCTCTTTCTCA
CCR6 rs2301436
Forward TTATACGTGTGGTGGCTGGA
Reverse AGTAAGGCGAGAAGGCACTG
IL12B rs10045431
Forward CAGTAGCAGTGGTGGAGCAA
Reverse TCAGCTGGACACCATTTTGA
TNF15SF15 rs4263839
Forward GTTGCTGGTTTCCCACTGTT
Reverse GCCAGA AGGTGAGATGGAGA
TNFSF2 rs1799964 rs4645836 rs1799724
Forward CCAGACTGCTGCAGGG
Reverse GAATTCACAGACCCCACTG
TNFSF2 rs1800629 rs361525
Forward TTTTCCCTCCAACCCCGT
Reverse CGGAAAACTTCCTTGGTGG
LRRK2 rs1175593
Forward ACAAATGGCCAAGAAGCATA
Reverse TTCATTGATGGACACTTAGATTGA
SNPZ single-nucleotide polymorphism.
Table 2 Demographic and clinical features of Crohn’s
disease patients
No. Percentage
Patients 110
Sex (male/female) 71/39 64.5/35.5
Age (y)a 30.5 (1.2e75)
Disease location
Ileum 21 19.1
Colon 20 18.2
Ileocolon 35 31.8
Ileumþ upper GI tract 12 10.9
Colonþ upper GI tract 9 8.2
Ileocolonþ upper GI tract 7 6.4
NA 6 5.4
Disease behavior
Inflammatory 46 41.8
Stenosing 37 33.6
Penetrating 27 24.6
Surgery 45 40.9
Mortality 3 2.7
a Value is given as median (range).
GIZ gastrointestinal; NAZ not available.
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date of diagnosis as pre-1989 and every 5 years after 1989,
until 2008. This showed that CD patient numbers had
doubled every 5 years during the past 20 years (Fig. 1). The
clinical characteristics are summarized in Table 2. The peak
age of onset of CD in Taiwan is 11e40 years (Fig. 2).Figure 1. Marked increase in new Crohn’s diagnosis, espe-
cially after 2004.The associated extraegastrointestinal tract manifesta-
tions were as follows: ankylosing spondylitis (4 of 110,
3.6%); juvenile rheumatoid arthritis (2 of 110, 1.8%);
erythema nodosum (3 of 110, 2.7%); uveitis (1 of 110, 0.9%);
and deep vein thrombosis (1 of 110, 0.9%). Major compli-
cations in these CD patients included marked gastrointes-
tinal tract bleeding (8 of 110, 7.3%); osteoporosis with
fracture (4 of 110, 3.6%); depression (1 of 110, 0.9%); small
bowel adenocarcinoma (1 of 110, 0.9%); intra-abdominal
abscess (6 of 110, 5.5%); and perforation (4 of 110, 3.6%).
Forty-five patients (40.9%) received either diagnostic or
complication-related surgery. Three patients (2.7%) died in
the follow-up period, all because of sepsis.
Genetic analysis
Among the 12 SNPs that were analyzed, two were signifi-
cantly different for the homozygous genotype: ATG16L1,Figure 2. Peak age of onset of Crohn’s disease in Taiwan.
Table 3 Summary of single-nucleotide polymorphism analysis
Gene ID Allele Genotype of CD (%) Sum Genotype of control (%) Sum Genotype 11
vs. 22 (Hom OR)
Genotype 12
vs. 22 (Het OR)
Trend
test
Allele 1 vs. 2
1 2 11 12 22 11 12 22 OR (95% CI) p OR (95% CI) p OR (95% CI) p
IL23R rs11209026 A G 0 0 39 (100) 39 0 0 100 (200) 100 d d d d d d d
IL23R rs11465804 G T 0 0 39 (100) 39 0 0 100 (200) 100 d d d d d d d
ATG16L1 rs2241880 A G 17 (44) 18 (46) 4 (10) 39 27 (27) 47 (47) 26 (26) 100 4.09
(1.21e13.79)
0.023 1.64
(0.73e3.71)
0.232 0.020 1.96
(1.14e3.39)
0.016
LRRK2 rs1175593 C T 9 (27) 17 (52) 7 (21) 33 26 (26) 47 (47) 27 (27) 100 1.34
(0.43e4.11)
0.615 1.40
(0.51e3.79)
0.514 0.626 1.15
(0.67e2.01)
0.619
CCR6 rs2301436 G A 21 (54) 13 (33) 5 (13) 39 37 (37) 52 (52) 11 (11) 100 1.25
(0.38e4.08)
0.713 0.55
(0.16e1.86)
0.337 0.233 1.40
(0.80e2.47)
0.239
IL12B rs10045431 A C 0 7 (18) 32 (82) 39 2 (2) 22 (22) 76 (76) 100 d d 0.76
(0.29e1.95)
0.561 0.355 0.66
(0.27e1.59)
0.354
TNFSF15 rs4263839 A G 16 (41) 17 (44) 6 (15) 39 24 (24) 45 (45) 31 (31) 100 3.44
(1.17e10.13)
0.025 1.77
(0.76e4.10)
0.187 0.022 2.82
(1.56e5.08)
<0.001
TNFSF2 rs361525 A G 0 1 (3) 38 (97) 39 1 (0.5) 5 (2.5) 194 (97) 200 d d 1.02
(0.12e8.99)
0.985 0.792 0.73
(0.09e6.01)
0.769
TNFSF2 rs1800629 A G 0 6 (15) 33 (85) 39 2 (1) 31 (15.5) 167 (83.5) 200 d d 0.98
(0.38e2.53)
0.966 0.762 0.87
(0.35e2.14)
0.760
TNFSF2 rs1799724 T C 0 10 (26) 29 (74) 39 0 (0) 47 (23.5) 153 (76.5) 200 d d 1.12
(0.51e2.47)
0.774 0.774 1.11
(0.53e2.29)
0.790
TNFSF2 rs4645836 A C 2 (5) 14 (36) 23 (59) 39 0 (0) 74 (37) 126 (63) 200 d d 1.04
(0.50e2.14)
0.923 0.301 1.32
(0.74e2.37)
0.349
TNFSF2 rs1799964 C T 2 (5) 15 (39) 22 (56) 39 1 (0.5) 71 (35.5) 128 (64) 200 11.64
(1.01e133.97)
0.094 1.23
(0.60e2.52)
0.573 0.175 1.44
(0.81e2.57)
0.212
CDZ Crohn’s disease; CIZ confidence interval; HetZ heterozygous; HomZ homozygous; ORZ odds ratio.
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604 S.-C. Wei et al.rs2241880dORZ 4.09, 95% CIZ 1.21e13.79, pZ 0.023;
and TNFSF15, rs4263839dORZ 3.44, 95% CIZ 1.17e10.13,
pZ 0.025. Although the p value for TNFSF2 rs1799964
homozygous genotype did not reach statistical significance
(pZ 0.094), the OR was 11.64 (95% CIZ 1.01e133.95).
Further study is probably merited to confirm its involve-
ment in CD. The results of the genetic analysis are
summarized in Table 3. Haplotype analysis of five SNPs on
TNFSF2 showed no significant linkage between these SNPs,
with a maximum D0 (normalized linkage disequilibrium
coefficient) of 0.84 between rs1799964 and rs4645836. The
haplotype in TNFSF2 was not a significant predictor of CD
risk.
Genotype and phenotype correlation
We further analyzed the possible correlation between the
ATG16L1 (rs2241880) and TNFSF15 (rs4263839) genotypes
and clinical phenotype. No correlation was identified
between ileum involvement, fistula formation, presence of
stenosis, surgical risk, and early onset of disease for
ATG16L1 (rs2241880) and TNFSF15 (rs4263839).
Discussion
Our results demonstrated that the incidence of CD in
Taiwan has increased markedly, especially since 2004. In
addition to our previous reports based on the pediatric
population,7 our results showed that the incidence of CD in
Taiwan has increased across the entire age range. Previous
reports from Japan, Korea, Singapore, and China have
shown that there is a trend for increased incidence of CD in
the Asia-Pacific area.23 Our results provide further evidence
to support this finding.
Comparing the clinical characteristics of CD patients in
Taiwan with those in other countries in Asia, we found
that patients here had “medium” expression, including
age of onset; male to female ratio; aggressive diseaseTable 4 Comparison of clinical and single-nucleotide polymorp
Japan18,21,27 Korea19,22,2
Clinical characteristics
Mean age of diagnosis (y) 22.4 23.5e24.2
M/F ratio 2.24e2.72 1.67e1.9
Disease behavior (%)
Inflammatory 26.1 43.7
Stricturing 50.6 29.5
Penetrating 22.2 26.8
Surgery (%) 69.3 13.1
Mortality rate (%) 1.1e5.1 NA
SNP results
ATG16L1 a 
TNFSF15 þ þ
IL23R  þ
a Not associated.
b Associated.
FZ female; MZmale; NAZ not available.pattern (penetrating, surgery); and the mortality rate
(Table 4).18,19,21,22,24e31 The peak age of onset of CD in
Taiwan was 11e40 years (Fig. 2), which was earlier than
that in other Asian areas (20e50 years).23,24 We also
observed a second small peak of onset at 61e70 years,
which is not common in Asian patients.23,24 Comparison of
the clinical parameters of these reports may require some
adjustments because the diagnosis and follow-up periods
differ.
According to the SNP analysis, we found that ATG16L1
(rs2241880) and TNFSF15 (rs4263839) were associated with
CD risk in Taiwan. This is the first time that ATG16L1 has
been found to be associated with CD in a non-Caucasian
population. ATG16L1 was identified as a CD susceptibility
gene in 2007.32 It has been reported to be a CD-associated
gene in Europe, New Zealand, Australia, and Canada,33e40
but not in Japan, Korea, China, and Brazil.18,25,26,41 Func-
tional analysis of this ATG16L1 variant has demonstrated
that the increase in CD risk is because of impaired bacterial
handling and lowered rates of bacterial capture by
autophagy.42
TNFSF15 was first identified to be associated with CD risk
in Japan by a genome-wide association study in 2005.21
Furthermore, it has been reported to be associated with
CD susceptibility in Korea and Europe.43,44 Patients carrying
the TNFSF15 (TL1A)-risk haplotype B have significantly
increased expression of membrane and soluble TL1A in
response to immune complexes.45 The promoter activity of
the risk allele is higher than that in the no-risk allele pop-
ulation in stimulated T cells. It may, therefore, confer an
increased susceptibility to CD.
In addition to IL23R, we did not find any association of
CD risk with the newly identified CD susceptibility genes
CCR6, LRRK2, and IL12B,2 nor with the previously reported
tumor necrosis factor-a promoter SNPs (TNFSF2). We were
not able to find an association between clinical character-
istics and SNP results. Only 39 patients underwent SNP
analysis, and the small number might be the reason why we
could not find any association. Enrollment of more cases inhism results in Asia
5,28 Singapore24,29 China26,30,31 Taiwan
32.5e37.1 32.6e33 30.5
0.8e1.67 2.32e2.5 1.82
56.9e60.0 30 41.8
24.6e28.6 24 33.6
11.4e18.5 46 24.5
12.5e42 27 40.9
1 NA 2.7
NA  þb
NA NA þ
NA NA 
Crohn’s disease in Taiwan 605the future might help us to confirm the association and
nonassociation among the SNPs and to find an association
between clinical and genetic phenotypes.
In conclusion, our results demonstrated that the inci-
dence of CD in Taiwan has markedly increased recently.
ATG16L1 and TNFSF15 are associated with CD susceptibility
in Taiwan. This is believed to be the first association noted
between ATG16L1 and non-Caucasian CD.Acknowledgments
This study was supported by a grant from the National
Taiwan University Hospital (NTUH-98-00021). The authors
thank the second Core Laboratory of the Department of
Medical Research of the National Taiwan University Hospital
for technical assistance.
The authors would like to thank the patients who
participated in this study, especially in the genetic analysis.
Healthy control samples were provided by Dr. Yi-Nin Su,
Department of Genetic Medicine.References
1. Himmel ME, Hardenberg G, Piccirillo CA, Steiner TS,
Levings MK. The role of T-regulatory cells and toll-like recep-
tors in the pathogenesis of human inflammatory bowel disease.
Immunology 2008;125:145e53.
2. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD,
et al. Genome-wide association defines more than 30 distinct
susceptibility loci for Crohn’s disease. Nat Genet 2008;40:
955e62.
3. Lee GH, Kim CG, Kim JS, Jung HC, Song IS. Frequency analysis
of NOD2 gene mutations in Korean patients with Crohn’s
disease. Korean J Gastroenterol 2005;45:162e8 [in Korean].
4. Hsiao CH, Wei SC, Wong JM, Lai HS, Chang MH, Ni YH. Pediatric
Crohn disease: clinical and genetic characteristics in Taiwan.
J Pediatr Gastroenterol Nutr 2007;44:342e6.
5. Li M, Gao X, Guo CC, Wu KC, Zhang X, Hu PJ. OCTN and CARD15
gene polymorphism in Chinese patients with inflammatory
bowel disease. World J Gastroenterol 2008;14:4923e7.
6. Yamazaki K, Takazoe M, Tanaka T, Kazumori T, Nakamura Y.
Absence of mutation in the NOD2/CARD15 gene among 483
Japanese patients with Crohn’s disease. J Hum Genet 2002;47:
469e72.
7. Tsai CH, Chen HL, Ni YH, Hsu HY, Jeng YM, Chang CJ, et al.
Characteristics and trends in incidence of inflammatory bowel
disease in Taiwanese children. J Formos Med Assoc 2004;103:
685e91.
8. Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L,
Weir DG, Mahmud N, et al. Inflammatory bowel disease: the
role of inflammatory cytokine gene polymorphisms. Mediators
Inflamm 2004;13:181e7.
9. Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine
gene polymorphisms in determining disease susceptibility and
phenotype in inflammatory bowel disease. Am J Gastroenterol
2005;100:1134e42.
10. Dalal I, Karban A, Wine E, Eliakim R, Shirin H, Fridlender M,
et al. Polymorphisms in the TNF-alpha promoter and variability
in the granulomatous response in patients with Crohn’s
disease. Pediatr Res 2006;59:825e8.
11. Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P,
Papalambros E, Archimandritis A, et al. Association between
polymorphisms in the Toll-like receptor 4, CD14, andCARD15/NOD2 and inflammatory bowel disease in the Greek
population. World J Gastroenterol 2005;11:681e5.
12. Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A,
Fuentes D, Nino P, et al. TNF-alpha-308Apromoter polymorphism
is associated with enhanced TNF-alpha production and inflam-
matory activity in Crohn’s patients with fistulizing disease. Am J
Gastroenterol 2003;98:1101e6.
13. Klein W, Tromm A, Griga T, Fricke H, Folwaczny C, Hocke M,
et al. A polymorphism in the CD14 gene is associated with
Crohn disease. Scand J Gastroenterol 2002;37:189e91.
14. Levine A, Karban A, Eliakim R, Shaoul R, Reif S, Pacht A, et al.
A polymorphism in the TNF-alpha promoter gene is associated
with pediatric onset and colonic location of Crohn’s disease.
Am J Gastroenterol 2005;100:407e13.
15. Matsukura H, Ikeda S, Yoshimura N, Takazoe M, Muramatsu M.
Genetic polymorphisms of tumour necrosis factor receptor
superfamily 1A and 1B affect responses to infliximab in Japa-
nese patients with Crohn’s disease. Aliment Pharmacol Ther
2008;27:765e70.
16. Sykora J, Subrt I, Didek P, Siala K, Schwarz J, Machalova V, et al.
Cytokine tumor necrosis factor-alpha A promoter gene poly-
morphism at position -308 G/A and pediatric inflammatory
bowel disease: implications in ulcerative colitis and Crohn’s
disease. J Pediatr Gastroenterol Nutr 2006;42:479e87.
17. Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC,
Bitton A, et al. Tumor necrosis factor receptor gene poly-
morphisms in Crohn’s disease: association with clinical
phenotypes. Am J Gastroenterol 2005;100:1126e33.
18. Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y,
Hata A. Association analysis of genetic variants in IL23R,
ATG16L1 and 5p13.1 loci with Crohn’s disease in Japanese
patients. J Hum Genet 2007;52:575e83.
19. Yang SK, Lee SG, Cho YK, Lim J, Lee I, Song K. Association of
TNF-alpha/LTA polymorphisms with Crohn’s disease in
Koreans. Cytokine 2006;35:13e20.
20. Zipperlen K, Peddle L, Melay B, Hefferton D, Rahman P. Asso-
ciation of TNF-alpha polymorphisms in Crohn disease. Hum
Immunol 2005;66:56e9.
21. Yamazaki K, McGovern D, Ragoussis J, Paolucci M, Butler H,
Jewell D, et al. Single nucleotide polymorphisms in TNFSF15
confer susceptibility to Crohn’s disease. Hum Mol Genet 2005;
14:3499e506.
22. Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, et al.
Management consensus of inflammatory bowel disease for the
Asia-Pacific region. J Gastroenterol Hepatol 2006;21:1772e82.
23. Thia KT, Loftus Jr EV, Sandborn WJ, Yang SK. An update on the
epidemiology of inflammatory bowel disease in Asia. Am
J Gastroenterol 2008;103:3167e82.
24. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K,
et al. A genome-wide association scan of nonsynonymous SNPs
identifies a susceptibility variant for Crohn disease in ATG16L1.
Nat Genet 2007;39:207e11.
25. Amre DK, Mack DR, Morgan K, Krupoves A, Costea I,
Lambrette P, et al. Autophagy gene ATG16L1 but not IRGM is
associated with Crohn’s disease in Canadian children. Inflamm
Bowel Dis 2009;15:501e7.
26. Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM,
Hayward NK, et al. ATG16L1 T300A shows strong associations
with disease subgroups in a large Australian IBD population:
further support for significant disease heterogeneity. Am J
Gastroenterol 2008;103:2519e26.
27. Glas J, Konrad A, Schmechel S, Dambacher J, Seiderer J,
Schroff F, et al. The ATG16L1 gene variants rs2241879 and
rs2241880 (T300A) are strongly associated with susceptibility
to Crohn’s disease in the German population. Am J Gastro-
enterol 2008;103:682e91.
28. Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L,
Kovacs A, et al. ATG16L1 and IL23 receptor (IL23R) genes are
606 S.-C. Wei et al.associated with disease susceptibility in Hungarian CD
patients. Dig Liver Dis 2008;40:867e73.
29. Latiano A, Palmieri O, Valvano MR, D’Inca R, Cucchiara S,
Riegler G, et al. Replication of interleukin 23 receptor and
autophagy-related 16-like 1 association in adult- and pediatric-
onset inflammatory bowel disease in Italy. World J Gastro-
enterol 2008;14:4643e51.
30. Newman WG, Zhang Q, Liu X, Amos CI, Siminovitch KA. Genetic
variants in IL-23R and ATG16L1 independently predispose to
increased susceptibility to Crohn’s disease in a Canadian pop-
ulation. J Clin Gastroenterol 2009;43:444e7.
31. Perricone C, Borgiani P, Romano S, Ciccacci C, Fusco G,
Novelli G, et al. ATG16L1 Ala197Thr is not associated with
susceptibility to Crohn’s disease or with phenotype in an Italian
population. Gastroenterology 2008;134:368e70.
32. Roberts RL, Gearry RB, Hollis-Moffatt JE, Miller AL, Reid J,
Abkevich V, et al. IL23R R381Q and ATG16L1 T300A are strongly
associated with Crohn’s disease in a study of New Zealand
Caucasians with inflammatory bowel disease. Am
J Gastroenterol 2007;102:2754e61.
33. Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N,
Babasukumar U, et al. CARD15 and IL23R influences Crohn’s
disease susceptibility but not disease phenotype in a Brazilian
population. Inflamm Bowel Dis 2008;14:674e9.
34. Yang SK, Park M, Lim J, Park SH, Ye BD, Lee I, et al. Contri-
bution of IL23R but not ATG16L1 to Crohn’s disease suscepti-
bility in Koreans. Inflamm Bowel Dis 2009;15:1385e90.
35. Zhi J, Zhi FC, Chen ZY, Yao GP, Guan J, Lin Y, et al. Correlation
of the autophagosome gene ATG16L1 polymorphism and
inflammatory bowel disease. Nan Fang Yi Ke Da Xue Xue Bao
2008;28:649e51 [in Chinese].
36. Kuballa P, Huett A, Rioux JD, Daly MJ, Xavier RJ. Impaired
autophagy of an intracellular pathogen induced by a Crohn’s
disease associated ATG16L1 variant. PLoS ONE 2008;3:e3391.37. Thiebaut R, Kotti S, Jung C, Merlin F, Colombel JF, Lemann M,
et al. TNFSF15 polymorphisms are associated with suscepti-
bility to inflammatory bowel disease in a new European
cohort. Am J Gastroenterol 2009;104:384e91.
38. Yang SK, Lim J, Chang HS, Lee I, Li Y, Liu J, et al. Association of
TNFSF15 with Crohn’s disease in Koreans. Am J Gastroenterol
2008;103:1437e42.
39. Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ,
et al. IBD-associated TL1A gene (TNFSF15) haplotypes deter-
mine increased expression of TL1A protein. PLoS ONE 2009;4:
e4719.
40. Kakuta Y, Ueki N, Kinouchi Y, Negoro K, Endo K, Nomura E,
et al. TNFSF15 transcripts from risk haplotype for Crohn’s
disease are overexpressed in stimulated T cells. Hum Mol
Genet 2009;18:1089e98.
41. Oriuchi T, Hiwatashi N, Kinouchi Y, Takahashi S, Takagi S,
Negoro K, et al. Clinical course and longterm prognosis of
Japanese patients with Crohn’s disease: predictive factors,
rates of operation, and mortality. J Gastroenterol 2003;38:
942e53.
42. Park JB, Yang SK, Myung SJ, Byeon JS, Lee YJ, Lee GH, et al.
Clinical characteristics at diagnosis and course of Korean
patients with Crohn’s disease. Korean J Gastroenterol 2004;
43:8e17 [in Korean].
43. Law NM, Lim CC, Chong R, Ng HS. Crohn’s disease in the
Singapore Chinese population. J Clin Gastroenterol 1998;26:
27e9.
44. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retro-
spective survey of 452 patients with inflammatory bowel
disease in Wuhan city, central China. Inflamm Bowel Dis
2006;12:212e7.
45. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of
Crohn’s disease in the Chinese population. Inflamm Bowel Dis
2004;10:646e51.
